Recursion (RXRX) reported top-line results of the SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for REC-994 in symptomatic Cerebral Cavernous Malformation patients. REC-994 met primary endpoint of safety and tolerability, showing a similar profile across placebo and both 200mg and 400mg dosage-arms with regard to the frequency and severity of adverse events after 12 months of treatment.
Recursion plans to present data from the trial at a forthcoming medical conference and intends to submit data for publication in a peer reviewed scientific journal.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com